Hu CT

No ORCID on file · 1 paper in corpus
2020
Medicine ·doi:10.1097/md.0000000000020808

RationalePalbociclib (PAL) is a first-in-class selective inhibitor of the cyclin-dependent kinases 4 (CDK4) and CDK6 and is indicated for the treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negati…